Bio-Assay Works to Demonstrate Groundbreaking Rapid Assays at AACC
8 Jul 2012
BioAssay Works is focused on antibody- (and antigen-) based detection technologies and their application in lateral-flow immunoassay, for both instrument-based and visually read tests. The company has substantial, trade-secret- protected intellectual property, especially in production of unique, high-sensitivity gold sols and gold conjugates, and has two of its own patented lateral-flow test platforms.
BioAssay Works offers four technologies for high-sensitivity, rapid-format lateral-flow assays. These include concentrated gold sol nanoparticles and rapid-assay development and custom conjugation services. The company’s patented C-FLAT® lateral-flow, rapid-assay platforms provides ultra-sensitive assays with ELISA-like sensitivity.
The skills of BioAssay Works were utilized by the clinical researchers at Brigham and Womens Hospital, Harvard University to convert a lab-based ELISA to a point-of-care urine dipstick for a new acute kidney damage biomarker. The requirement was to have similar sensitivity in the fifteen-minute dipstick as the ELISA test. BioAssay Works has been the only company able to develop a point-of-care format assay for this important kidney damage biomarker that is currently being used world-wide for toxicity research.
The rapid assay detects kidney injury molecule-1 (Kim-1), which has been qualified by the Food and Drug Administration and European Medicines Agency as a highly sensitive and specific urinary biomarker to monitor drug-induced kidney injury in preclinical studies and on a case-by-case basis in clinical trials.
The new KIM-1 acute kidney marker rapid assay and ELISA will be displayed at the BioAssay Works booth (#841) at the AACC Clinical lab Expo 2012 in Los Angeles, July 15th-19th.
Related Products
Request Quote for All Products
C-FLAT® Counter-Flow Lateral Amplified Test
BioAssay Works, LLCPatented lateral-flow platform contributes to an increased sensitivity, with a rapid assay platform that avoids current patent constraints. Not only is it a new patented platform, but the increased performance of this assay platform can offer you ELISA-like sensitivity in a lateral-flow format.
Gold Sols and Gold Conjugates
BioAssay Works, LLC10 OD to 50 OD concentrated nanoparticles that have been optimized for rapid assays without the traditional boiling and centrifugation steps. The BioAssay Works gold sol production process is unique, by eliminating the boiling step, and because of the concentrated gold, you do not have to dilute the sols prior to conjugation, nor do they have to be centrifuged to remove free antibody. The elimination of these two steps alone immediately contributes to the gold sol consistency, reduction of assay development problems and cost savings for manufacturing. The proprietary process reduces the problem of polymers and aggregates, and this optimizes performance in your rapid assays.